Ambri to evaluate SensiDX in hospitals
31 May, 2004 by Melissa TrudingerAmbri (ASX:ABI) has installed its SensiDX System at the Royal North Shore Hospital in Sydney for evaluation and expects to install a second system at Sydney's St Vincent's Hospital shortly.
New faces at the Bionomics
27 May, 2004 by Graeme O'NeillAdelaide drug-discovery company Bionomics (ASX:BNO, US OTC:BMICY) has appointed Dr Tim Harris, CEO and co-founder of US biotech Structural GenomiX, to its advisory board.
Ventracor pilot trial to continue
27 May, 2004 by Renate KrelleSydney-based Ventracor (ASX:VCR) today announced its pilot trial, testing the safety of its VentrAssist artifical heart device, will continue.
Phosphagenics seeks listing on UK's AIM
26 May, 2004 by Renate KrelleMelbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
CSL outsources anti-venom production to PlasVacc
25 May, 2004 by Melissa TrudingerQueensland based veterinary plasma company PlasVacc has signed and agreement to supply CSL with horse plasma for anti-venom applications.
Fed decision backs GSK lawsuit, says Biota
25 May, 2004 by Melissa TrudingerA federal government decision earlier this month to stockpile Roche's Tamiflu, rather than the anti-flu drug Relenza, designed by Melbourne-based Biota (ASX:BTA), is being used by the Australian firm to support its legal claims that GlaxoSmithKline failed to support and promote Relenza.
Cryosite and Peter Mac team up to store stem cells
24 May, 2004 by Melissa TrudingerSydney-based cryogenic storage company Cryosite (ASX: CTE) has entered into an agreement with Melbourne's Peter MacCallum Cancer Centre to provide long term storage of patients' blood stem cells.
Parental approval for BioPharmica spin off, prospectus launched
24 May, 2004 by Melissa TrudingerThe spin-off and listing of BioPharmica was approved at a general meeting of Grandbridge (ASX: GBA) shareholders today by more than 99 per cent of shareholders.
Playing it safe in science can cause lasting harm: academy president
21 May, 2004 by Graeme O'NeillThe President of the Australian Academy of Science, Dr Jim Peacock, has warned that governments could do “irreparable and lasting harm” by seeking to play safe when confronted by controversial technological change.
AustCancer snaps up US vaccine developer
21 May, 2004 by Melissa TrudingerAustralian Cancer Technologies (AustCancer, ASX: ACU) is the latest Australian company to announce an acquisition of a US company, with its proposal to acquire US vaccine developer Galenica Pharmaceuticals for around US$5 million in shares.
The GM ban: what it will mean for plant biotech
20 May, 2004 by Graeme O'NeillThe future of the Victorian wheat industry has moved from a biosecure glasshouse into a small, netted field plot at the International Centre for Cereal Breeding (CIMMYT) in Mexico.
Political science: behind the GM ban
20 May, 2004 by Graeme O'NeillAlmost two months ago, the Victorian Labor government stunned the state's biotechnology industry by imposing a four-year, legislated moratorium on genetically modified (GM) canola cropping.
Living Cell Technologies issues prospectus for $7 million ASX listing
20 May, 2004 by Melissa TrudingerCell therapeutics company Living Cell Technologies has issued a prospectus to raise almost AUD$7 million through both a rights issue and a general issue.
Independent trial affirms potential of Chemeq’s antimicrobial
20 May, 2004 by Graeme O'NeillAn independent trial of the polymeric antimicrobial developed by Perth pharmaceutical company Chemeq (ASX:CMQ) has confirmed the drug’s potential to improve disease control in the poultry industry, while transforming its knife-edge economics.
Regenera to list in early June
19 May, 2004 by Renate KrelleThe CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
